Friday’s Highlights at Noon: Anthera Pharmaceuticals (ANTH), Akorn (AKRX), Vivus (VVUS), ImmunoCellular Therapeutics (IMUC), Titan Pharmaceuticals (TTNP)

So far Friday, December 7, NASDAQ is down -5.35% and the S&P is down -3.63%. Here are this morning’s most active stocks: Anthera Pharmaceuticals (ANTHResearch Report), Akorn (AKRXResearch Report), Vivus (VVUSResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report) and Titan Pharmaceuticals (TTNPResearch Report).

Anthera Pharmaceuticals is up 55.26% in midday trading to $0.06. Shares opened today at $0.04. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Akorn is down -18.94% in midday trading to $4.52. Shares opened today at $5.57. The company has a 52-week low of $3.54 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $13.80, marking a 147.76% potential upside from current levels. In a report issued on November 27, Piper Jaffray analyst David Amsellem reiterated a Buy rating on AKRX, with a price target of $9, which implies an upside of 62% from current levels. Separately, on November 7, RBC’s Randall Stanicky maintained a Hold rating on the stock and has a price target of $9.

Vivus is up 16.81% in midday trading to $2.99. Shares opened today at $2.56. The company has a 52-week low of $2.52 and a 52-week high of $0.00. In the last 30 days, insiders purchased $40.7K worth of VVUS shares. Over the last 3 months, the insider sentiment on Vivus has been positive based on 40 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

ImmunoCellular Therapeutics is down -10.71% in midday trading to $0.03. Shares opened today at $0.03. The company has a 52-week low of $0.02 and a 52-week high of $0.00.

Titan Pharmaceuticals is up 9.52% in midday trading to $0.29. Shares opened today at $0.26. The company has a 52-week low of $0.17 and a 52-week high of $0.00. Over the last 3 months, the insider sentiment on Titan Pharmaceuticals has been positive based on 7 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leave a Reply

Your email address will not be published. Required fields are marked *